A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT07287150)
A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.
Who can join: Review the eligibility criteria below.
Location: VA West Los Angeles Medical Center - (CRS) - NAVREF - PPDS — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (47 Sites)
Showing the first 25 of 47 sites.
- VA West Los Angeles Medical Center - (CRS) - NAVREF - PPDS — Los Angeles, California
- UCSF — San Francisco, California
- Holden Comprehensive Cancer Center — Iowa City, Iowa
- Montefiore Einstein Cancer Center — The Bronx, New York
- Lifespan Cancer Institute — Providence, Rhode Island
- Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Royal North Shore Hospital-Pacific Hwy — St Leonards, New South Wales
- Sunshine Coast University Hospital — Birtinya, Queensland
- Royal Brisbane & Womens Hospital — Herston, Queensland
- Box Hill Hospital — Box Hill, Victoria
- Irmandade Da Santa Casa de Misericordia de Porto Alegre — Porto Alegre, Rio Grande do Sul
- CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia — Santo André, São Paulo
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS — São José do Rio Preto, São Paulo
- Instituto Nacional de Cancer - INCa — Rio de Janeiro,
- Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira - ICESP — São Paulo,
- Princess Margaret Cancer Centre — Toronto, Ontario
- Centre de recherche du Centre Hospitalier de l'Universite de Montreal — Montreal, Quebec
- Jewish General Hospital — Montreal, Quebec
- EDOG - Institut Bergonie - PPDS — Bordeaux, Gironde
- Gustave Roussy — Villejuif, Val-de-Marne
- Centre Léon Bérard — Lyon,
- Institut Paoli Calmettes — Marseille,
- Universitätsklinikum Freiburg — Freiburg im Breisgau, Baden-Wurttemberg
- Universitätsklinikum Hamburg-Eppendorf — Hamburg,
- Studienpraxis Urologie — Nürtingen,
📞 Contact the Study Coordinator
Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Castration-Resistant Prostate Cancer
- A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer — San Francisco, California
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment — Tucson, Arizona
- ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC — Sacramento, California
- FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Duarte, California
- A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer — Duarte, California
- FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer — San Francisco, California
Explore by condition: All Metastatic Castration-Resistant Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.